PAVMED INC (PAVM) Stock Price, Quote, News and Overview
NASDAQ:PAVM - Nasdaq - US70387R4039 - Common Stock - Currency: USD
PAVM Quote, Performance and Key Statistics
0.6
-0.02 (-2.9%)
The current stock price of PAVM is 0.6 USD. In the past month the price decreased by -2.52%. In the past year, price decreased by -26.38%.
PAVM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.11 | 233.80B | ||
| ISRG | INTUITIVE SURGICAL INC | 69.86 | 191.29B | ||
| BSX | BOSTON SCIENTIFIC CORP | 39.46 | 157.61B | ||
| SYK | STRYKER CORP | 31.41 | 150.40B | ||
| MDT | MEDTRONIC PLC | 15.64 | 110.32B | ||
| BDX | BECTON DICKINSON AND CO | 12.13 | 48.97B | ||
| EW | EDWARDS LIFESCIENCES CORP | 30.08 | 45.88B | ||
| IDXX | IDEXX LABORATORIES INC | 46.61 | 43.06B | ||
| RMD | RESMED INC | 28.1 | 37.41B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.17 | 34.06B | ||
| DXCM | DEXCOM INC | 52.32 | 33.85B | ||
| STE | STERIS PLC | 25.57 | 23.46B |
Related stock screener links
About PAVM
Company Profile
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The company went IPO on 2016-07-27. The firm operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Company Info
PAVMED INC
360 Madison Avenue, 25th Floor
New York City NEW YORK 10165 US
CEO: Lishan Aklog
Employees: 39
Phone: 12129494319
PAVMED INC / PAVM FAQ
What is the stock price of PAVMED INC today?
The current stock price of PAVM is 0.6 USD. The price decreased by -2.9% in the last trading session.
What is the ticker symbol for PAVMED INC stock?
The exchange symbol of PAVMED INC is PAVM and it is listed on the Nasdaq exchange.
On which exchange is PAVM stock listed?
PAVM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PAVMED INC stock?
8 analysts have analysed PAVM and the average price target is 11.73 USD. This implies a price increase of 1855% is expected in the next year compared to the current price of 0.6. Check the PAVMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PAVMED INC worth?
PAVMED INC (PAVM) has a market capitalization of 10.57M USD. This makes PAVM a Nano Cap stock.
How many employees does PAVMED INC have?
PAVMED INC (PAVM) currently has 39 employees.
What are the support and resistance levels for PAVMED INC (PAVM) stock?
PAVMED INC (PAVM) has a support level at 0.59 and a resistance level at 0.62. Check the full technical report for a detailed analysis of PAVM support and resistance levels.
Is PAVMED INC (PAVM) expected to grow?
The Revenue of PAVMED INC (PAVM) is expected to decline by -96.01% in the next year. Check the estimates tab for more information on the PAVM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PAVMED INC (PAVM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PAVM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PAVM, evaluating the profitability, health, valuation and growth aspects
- PAVMED INC (PAVM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PAVMED INC (PAVM) Sales and EPS estimates to see what analysts future expectations are.
- PAVMED INC (PAVM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PAVMED INC (PAVM) Insider and Institutional Ownership to learn about the owners and their transactions.
- PAVMED INC (PAVM) Stock Chart to make your own analysis
- PAVMED INC (PAVM) Latest news and press-releases to stay up to date.
Does PAVMED INC (PAVM) stock pay dividends?
PAVM does not pay a dividend.
When does PAVMED INC (PAVM) report earnings?
PAVMED INC (PAVM) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of PAVMED INC (PAVM)?
The PE ratio for PAVMED INC (PAVM) is 0.68. This is based on the reported non-GAAP earnings per share of 0.88 and the current share price of 0.6 USD. Check the full fundamental report for a full analysis of the valuation metrics for PAVM.
What is the Short Interest ratio of PAVMED INC (PAVM) stock?
The outstanding short interest for PAVMED INC (PAVM) is 2.56% of its float. Check the ownership tab for more information on the PAVM short interest.
PAVM Technical Analysis
PAVM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PAVM. Both the profitability and financial health of PAVM have multiple concerns.
PAVM Financial Highlights
Over the last trailing twelve months PAVM reported a non-GAAP Earnings per Share(EPS) of 0.88. The EPS increased by 109.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3635.17% | ||
| ROA | 137.15% | ||
| ROE | 154.17% | ||
| Debt/Equity | 0.14 |
PAVM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PAVM. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 72.05% and a revenue growth -96.01% for PAVM